Leponex (Clozapine)

• Clozapine is used in psychiatric disorders where dopamine and serotonin pathways are implicated.
• Treatment‑resistant schizophrenia: provides significant reduction in positive and negative psychotic symptoms in patients who have not responded adequately to at least two other antipsychotic agents.
• Schizoaffective disorder: helps achieve mood stabilization and control of hallucinations or delusions in individuals with concurrent mood and psychotic symptoms.
• Suicidal behavior in schizophrenia: demonstrated to lower the incidence of suicide attempts and completions among patients with schizophrenia who exhibit persistent suicidal ideation.

• Clozapine acts as a multi‑receptor antagonist, blocking dopamine D2 and serotonin 5‑HT2A receptors while also inhibiting D4, 5‑HT2C, α1‑adrenergic, muscarinic and histamine H1 receptors. This broad receptor profile reduces dopaminergic overactivity and modulates serotonergic transmission, contributing to its efficacy in refractory psychosis and mood stabilization. The combined antagonism leads to decreased positive symptom expression and mitigates mood dysregulation, while the affinity for muscarinic and histamine receptors contributes to its distinctive side‑effect profile.

Clozapine may cause a range of adverse reactions, varying from mild to potentially life‑threatening.

Common Side Effects

• Sedation: feeling of drowsiness or fatigue.
• Weight gain: increase in appetite leading to body weight increase.
• Constipation: reduced bowel movements causing discomfort.
• Salivation: excessive drooling, especially at night.

Serious or Rare Side Effects

• Agranulocytosis: severe reduction in white blood cells requiring regular blood monitoring.
• Myocarditis: inflammation of the heart muscle that can present with chest pain or flu‑like symptoms.
• Seizures: risk of convulsive episodes, particularly at higher doses.
• Orthostatic hypotension: sudden drop in blood pressure upon standing causing dizziness.

Clozapine requires careful monitoring and specific precautions to ensure patient safety.

• Blood monitoring: weekly complete blood count for the first 6 months, then bi‑weekly to monthly as advised.
• Dose titration: start low and increase gradually to minimize hypotension and seizures.
• Smoking status: adjust dose if patient stops smoking, as nicotine induces metabolism.
• Pregnancy: contraindicated in pregnancy (Category D); risk to fetus outweighs benefits.
• Concomitant medications: avoid drugs that depress bone marrow or increase clozapine levels.
• Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture and light.

Clozapine interacts with several medicines, some of which require avoidance and others close monitoring.

Major Interactions (Avoid)

• CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin): can raise clozapine plasma levels, increasing toxicity risk.
• Myelosuppressive agents (e.g., carbamazepine, cyclophosphamide): may exacerbate agranulocytosis.
• CNS depressants (e.g., benzodiazepines, opioids): heighten sedation and respiratory depression.

Moderate Interactions (Monitor Closely)

• Smoking cessation: loss of CYP1A2 induction may increase clozapine concentrations; dose adjustment may be needed.
• Anticholinergic drugs (e.g., diphenhydramine): may worsen constipation and urinary retention.
• Lipid‑lowering agents (e.g., statins): may affect clozapine metabolism; monitor lipid profile and side effects.